A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.

Yuichi NagakawaYuichi HosokawaHidetsugu NakayamaYatsuka SaharaChie TakishitaTetsushi NakajimaYousuke HijikataKazuhiko KasuyaKenji KatsumataKoichi TokuuyeAkihiko Tsuchida

Published in: Cancer chemotherapy and pharmacology (2017)

Concurrent IMRT with gemcitabine and S-1 for patients is feasible as NACRT for BR-A with low gastrointestinal toxicity. IMRT can be employed as a standard radiotherapy to provide more effective NACRT with powerful chemotherapy drugs.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
patient reported outcomes
radiation induced
placebo controlled